#USA #San Diego #Oligonucleotide Synthesis #Tsingke Biotech #GMP Production

Tsingke Biotech's Participation at TIDES USA 2025

Tsingke Biotech, a pioneering force in biotechnology, recently showcased its cutting-edge capabilities at TIDES USA 2025, the premier international event dedicated to oligonucleotide and peptide therapeutics. Held in San Diego from May 19 to 22, the conference attracted a diverse array of industry professionals seeking the latest advancements in nucleic acid synthesis.

As a prominent exhibitor, Tsingke Biotech presented its revolutionary concept known as "The Great Gene Factory". This integrated model is designed to facilitate precision synthesis solutions that span the entire spectrum, from early discovery phases to large-scale manufacturing. The potential applications of Tsingke's technologies cover a wide range of therapeutic areas, significantly influencing the landscape of drug development.

Tsingke's exhibit highlighted its extensive service offerings, including:

• - End-to-End Synthesis Tools: The innovative Syn-HCY series synthesizers (12P/192P/768B) enable high-throughput production of oligonucleotides, catering to CRISPR technology, in vitro diagnostics, and various research needs.
• - GMP Production Systems: Featuring the Syn-HL12 synthesizer capable of producing between 200 nmol to 12 mmol, this system is equipped with real-time monitoring capabilities for UV, pH, and conductivity, ensuring high standards of quality and compliance.
• - Comprehensive Application Coverage: Tsingke Biotech supports multiple applications including antisense oligonucleotides (ASO), small interfering RNA (siRNA) therapeutics, gene editing, mRNA vaccine templates, as well as diagnostic probes.
• - Robust Chemical Modifications: With over 300 types of chemical modifications available, Tsingke Biotech ensures impressive batch-to-batch consistency, aided by a resilient supply chain for raw materials.

Attendees at the event expressed their admiration for Tsingke's automation skills and the flexibility of its modular equipment, which is engineered for the synthesis of high-purity, long-chain, and intensely modified oligonucleotides. The company's notable ability to seamlessly integrate reagents, instruments, and services into a cohesive platform has drawn significant interest from both pharmaceutical companies and biotechnology firms seeking collaborative partnerships.

As Tsingke Biotech continues to solidify its reputation within the life sciences sector, it remains committed to driving innovation in therapeutic approaches through its world-class nucleic acid synthesis platform. The team is enthusiastic about potential collaborations and inquiries that may arise from the connections made at TIDES USA 2025.

For further information or collaboration inquiries, interested parties can reach out via email at [email protected] or visit the company website at www.tsingke.com. Tsingke Biotech aspires to empower researchers and developers with the tools necessary for groundbreaking therapeutics and advancements in the field of biotechnology.